Centocor, Inc.
800 Ridgeview Drive
Horsham
Pennsylvania
19044
United States
Tel: 610-651-6000
Fax: 610-651-6100
Website: http://www.centocor.com/
About Centocor, Inc.
Centocor is harnessing the power of world-leading research and biomanufacturing to deliver innovative biomedicines that transform patients' lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Centocor products have also saved lives in the treatment of heart attacks and have been used to reduce risk of cardiac events in interventional cardiology.Centocor continues to pioneer new pathways in biomedical research and development. Drug discovery and development efforts focus on the following therapeutic areas: I.M.I.D. (Immune Mediated Inflammatory Diseases) hematology/oncology, infectious diseases, metabolic diseases, inflammatory bowel disorders, pulmonary disorders, central nervous system disorders, dermatology, rheumatology and cardiovascular disease. Centocor is looking for novel approaches that address the pathology of these diseases.
The world leader in monoclonal antibody production and technology, Centocor has brought critical biologic therapies to patients suffering from debilitating immune disorders. Centocor, Inc. is a wholly owned subsidiary of Johnson & Johnson, a worldwide manufacturer of healthcare products.
Products:
REMICADE is the global market leader among anti-tumor necrosis factor alpha (TNF-alpha) therapies and the only agent approved for the treatment of both rheumatoid arthritis (RA) and Crohn's disease (CD) in North America, the European Union (EU) and Japan. In the EU and in the U.S., REMICADE is approved for the treatment of active ankylosing spondylitis (AS) and psoriatic arthritis.
Senior Officers: Julie McHugh, President
Last Updated: 07-13-05
76 articles about Centocor, Inc.
-
X-Vax Technology is ready to submit an IND application to the U.S. FDA for its experimental herpes vaccine against HSV-1 and -2. Here's what you need to know.
-
IGM Biosciences, a privately-held biotech company located in Mountain View, California, announced that Daniel S. Chen will be the company’s new chief medical officer. Chen arrives from Genentech/Roche, where he was most recently vice president, Global Head of Cancer Immunotherapy.
-
Centocor, Inc. Acquires RespiVert Ltd., Strengthens Pulmonary Focus
6/1/2010
-
Edison Pharmaceuticals, Inc. Licenses Drug from Centocor, Inc. for Rare Diseases
1/5/2010
-
FDA Extends Review of Centocor, Inc. (JOBS) Psoriasis Drug
5/27/2009
-
Why Drug Companies Prefer Twitter Over Blogs; AstraZeneca PLC, Johnson & Johnson, Centocor, Inc., and GlaxoSmithKline Reviewed
5/21/2009
-
Centocor, Inc.'s Psoriasis Drug May Ease Psoriatic Arthritis, Tufts University Study
2/13/2009
-
FASgen, Inc. Announces Research and License Agreement With Centocor, Inc.
1/6/2009
-
Crucell N.V. Announces STAR(R) Research and Commercial License Agreement with Centocor, Inc.
1/6/2009
-
MorphoSys AG Announces Second Clinical Milestone in Therapeutic Antibody Program
12/11/2008
-
GeneNews Provides Centocor, Inc. Access to its Osteoarthritis Program
12/11/2008
-
MEDVERSATION(TM) Website Launched by Centocor, Inc. to Facilitate Physician-Patient Dialogue About Drug Benefits and Risks
11/12/2008
-
Centocor, Inc. Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis
10/27/2008
-
FDA Extends Centocor, Inc. Review Timeline for Ustekinumab Biologic License Application Three Months
8/8/2008
-
Medarex, Inc. Receives Milestone Payment for Acceptance of Investigational New Drug Application
7/23/2008
-
NJ to Lose More Than 800 Pharmaceutical Jobs; Johnson & Johnson (JOBS) Shifting 260 Jobs to Centocor, Inc.; Schering-Plough Corporation (JOBS) Cutting 500 and Abbott Laboratories (JOBS) Cutting 83
7/9/2008
-
Centocor, Inc. Submits Application to FDA (JOBS) Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
6/27/2008
-
Centocor, Inc. Phase 3 Data Show Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Previously Treated with Anti-TNF Agents
6/11/2008
-
Centocor, Inc. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
5/20/2008
-
Ortho Biotech Products, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product
5/16/2008